All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

cyproheptadine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
histamine-H1 receptor antagonists, tricyclic compounds	765	129-03-3

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: periactin cyproheptadine cyproheptadine hydrochloride cycloheptadine periactinol cyproheptadine HCl	A serotonin antagonist and a histamine H1 blocker used as antipruritic, appetite stimulant, antiallergic, and for the post-gastrectomy dumping syndrome, etc. Molecular weight: 287.41 Formula: C21H21N CLOGP: 5.16 LIPINSKI: 1 HAC: 1 HDO: 0 TPSA: 3.24 ALOGS: -4.33 ROTB: 0 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Drug dosage:

Dose	Unit	Route
12	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	3.64 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	0.50 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	1.74 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Unit	Confidence	Similarity
kinase-safety-class	ACVR2A,ACVR2B,AKT2,AKT3,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,CHEK1,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GSK3B,ITK,JAK2,JAK3,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPK9,MAPKAPK2,MET,MTOR,NTRK2,PDK4,PDPK1,PIK3CB,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,TEK,TGFBR1,TTK	46
kinase-selectivity-class	ACVR2B,AXL,BRAF,CAMK2D,MAPK7,SIK2,STK33,TTK	8
pfas-class	PFAS structural alert (1 = True, 0 = False)	0

Approvals:

Date	Agency	Company	Orphan
Oct. 17, 1961	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Infective pulmonary exacerbation of cystic fibrosis	209.57	19.94	59	5515	10220	90612653
Torus fracture	116.26	19.94	18	5556	151	90622722
Growth retardation	73.95	19.94	18	5556	1765	90621108
Serotonin syndrome	73.34	19.94	39	5535	37848	90585025
Agitation	62.04	19.94	43	5531	67055	90555818
Immobile	51.24	19.94	18	5556	6380	90616493
Irritability	38.08	19.94	25	5549	35637	90587236
Apallic syndrome	37.98	19.94	9	5565	787	90622086
Butterfly rash	37.60	19.94	11	5563	2174	90620699
Oesophageal spasm	36.96	19.94	12	5562	3349	90619524
Juvenile idiopathic arthritis	34.97	19.94	12	5562	3965	90618908
Hospitalisation	34.60	19.94	41	5533	128059	90494814
Bone density decreased	33.96	19.94	18	5556	17327	90605546
Oesophageal pain	33.86	19.94	12	5562	4362	90618511
Mood swings	33.66	19.94	19	5555	20683	90602190
Hallucination	32.15	19.94	29	5545	65930	90556943
Sleep apnoea syndrome	30.87	19.94	21	5553	31726	90591147
Malnutrition	30.08	19.94	17	5557	18541	90604332
Crying	27.43	19.94	18	5556	25627	90597246
Intentional overdose	26.94	19.94	31	5543	93803	90529070
Disturbance in social behaviour	26.86	19.94	10	5564	4178	90618695
Hallucination, tactile	26.41	19.94	6	5568	436	90622437
Dermatitis atopic	26.39	19.94	17	5557	23455	90599418
Mydriasis	25.00	19.94	14	5560	14998	90607875
Regurgitation	24.90	19.94	8	5566	2158	90620715
Mental status changes	24.49	19.94	21	5553	44658	90578215
Central obesity	23.93	19.94	7	5567	1383	90621490
Lymphoedema	23.38	19.94	13	5561	13740	90609133
Aggression	22.10	19.94	16	5558	26652	90596221
Psychomotor hyperactivity	21.48	19.94	12	5562	12801	90610072
Sinus tachycardia	21.15	19.94	16	5558	28497	90594376
Cardiogenic shock	21.01	19.94	15	5559	24453	90598420
Mood altered	20.72	19.94	13	5561	17131	90605742
Cystic fibrosis	20.22	19.94	8	5566	3933	90618940

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Infective pulmonary exacerbation of cystic fibrosis	169.13	20.67	53	4412	7765	42609105
Serotonin syndrome	164.17	20.67	71	4394	25774	42591096
Nasal polyps	66.43	20.67	22	4443	3829	42613041
Chronic sinusitis	65.07	20.67	21	4444	3371	42613499
Nasal congestion	45.98	20.67	32	4433	29469	42587401
Drug dependence	44.04	20.67	31	4434	29063	42587807
Cystic fibrosis	40.54	20.67	13	4452	2042	42614828
Irritability	40.34	20.67	29	4436	28099	42588771
Withdrawal syndrome	37.99	20.67	22	4443	14753	42602117
Clonus	37.30	20.67	14	4451	3506	42613364
Rhinorrhoea	37.16	20.67	29	4436	31765	42585105
Mood swings	36.40	20.67	18	4447	8808	42608062
Symptom masked	32.32	20.67	9	4456	872	42615998
Cystic fibrosis respiratory infection suppression	31.49	20.67	7	4458	268	42616602
Obsessive-compulsive symptom	27.08	20.67	6	4459	226	42616644
Anti-saccharomyces cerevisiae antibody	26.03	20.67	4	4461	17	42616853
Obsessive-compulsive disorder	25.59	20.67	13	4452	6730	42610140
Viral infection	25.17	20.67	20	4445	22463	42594407
Restlessness	24.47	20.67	22	4443	29227	42587643
Abdominal pain	24.01	20.67	58	4407	190413	42426457
Hospitalisation	23.98	20.67	34	4431	74296	42542574
Decreased appetite	22.42	20.67	57	4408	193080	42423790

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Infective pulmonary exacerbation of cystic fibrosis	305.96	16.93	91	8754	14680	110565774
Serotonin syndrome	235.16	16.93	108	8737	59045	110521409
Irritability	74.85	16.93	47	8798	47762	110532692
Torus fracture	64.35	16.93	11	8834	135	110580319
Mood swings	61.54	16.93	32	8813	22780	110557674
Drug dependence	58.49	16.93	41	8804	49979	110530475
Nasal polyps	52.06	16.93	24	8821	13176	110567278
Withdrawal syndrome	52.02	16.93	32	8813	31348	110549106
Agitation	51.66	16.93	54	8791	112997	110467457
Cystic fibrosis	48.08	16.93	17	8828	4714	110575740
Intentional overdose	43.01	16.93	53	8792	132448	110448006
Growth retardation	41.07	16.93	13	8832	2569	110577885
Obsessive-compulsive disorder	41.05	16.93	17	8828	7224	110573230
Mental status changes	39.58	16.93	39	8806	76083	110504371
Clonus	38.01	16.93	17	8828	8699	110571755
Restlessness	37.30	16.93	33	8812	56226	110524228
Hospitalisation	36.91	16.93	51	8794	142442	110438012
Symptom masked	36.29	16.93	11	8834	1884	110578570
Chronic sinusitis	35.13	16.93	23	8822	25061	110555393
Butterfly rash	35.02	16.93	11	8834	2120	110578334
Oesophageal spasm	32.84	16.93	12	8833	3654	110576800
Apallic syndrome	32.70	16.93	9	8836	1097	110579357
Pulmonary function test decreased	31.77	16.93	15	8830	8685	110571769
Malnutrition	31.04	16.93	22	8823	27257	110553197
Dermatitis atopic	30.00	16.93	21	8824	25520	110554934
Oesophageal pain	28.94	16.93	12	8833	5113	110575341
Nasal congestion	28.22	16.93	37	8808	98245	110482209
Anti-saccharomyces cerevisiae antibody	27.11	16.93	4	8841	17	110580437
Juvenile idiopathic arthritis	27.10	16.93	12	8833	5995	110574459
Obsessive-compulsive symptom	26.61	16.93	6	8839	323	110580131
Aggression	26.53	16.93	28	8817	59182	110521272
Regurgitation	26.09	16.93	10	8835	3475	110576979
Crying	25.37	16.93	19	8826	25609	110554845
Sleep apnoea syndrome	25.37	16.93	23	8822	40424	110540030
Suicide attempt	25.27	16.93	36	8809	103358	110477096
Hyperreflexia	24.70	16.93	13	8832	9472	110570982
Cystic fibrosis respiratory infection suppression	24.24	16.93	6	8839	483	110579971
Hyperthermia	23.85	16.93	17	8828	21255	110559199
Electrocardiogram QT prolonged	23.82	16.93	36	8809	108924	110471530
Pneumonia aspiration	22.42	16.93	30	8815	81203	110499251
Tachycardia	22.06	16.93	53	8792	226592	110353862
Muscle rigidity	21.99	16.93	17	8828	24014	110556440
Gastric hypomotility	21.64	16.93	5	8840	300	110580154
Decreased appetite	21.48	16.93	85	8760	475761	110104693
Immobile	21.33	16.93	11	8834	7691	110572763
Rhinorrhoea	21.15	16.93	33	8812	102633	110477821
Drug interaction	19.95	16.93	86	8759	500097	110080357
Hallucination, tactile	19.90	16.93	6	8839	1009	110579445
Medulloblastoma	19.73	16.93	4	8841	129	110580325
Sedation	19.64	16.93	26	8819	69657	110510797
Respiratory failure	19.52	16.93	49	8796	215283	110365171
Central obesity	19.49	16.93	7	8838	2029	110578425
Disturbance in social behaviour	19.33	16.93	9	8836	5049	110575405
Lymphoedema	19.24	16.93	13	8832	14916	110565538
Mydriasis	18.82	16.93	15	8830	22142	110558312
Abdominal pain	18.79	16.93	86	8759	512903	110067551
Product dose omission issue	18.32	16.93	62	8783	321720	110258734
Limb asymmetry	17.82	16.93	5	8840	653	110579801
Psychomotor hyperactivity	17.81	16.93	14	8831	20263	110560191
Palpitations	17.43	16.93	39	8806	159173	110421281
Intentional product misuse	17.37	16.93	35	8810	132869	110447585
Mood altered	17.16	16.93	14	8831	21361	110559093

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	R06AX02	RESPIRATORY SYSTEM ANTIHISTAMINES FOR SYSTEMIC USE ANTIHISTAMINES FOR SYSTEMIC USE Other antihistamines for systemic use
MeSH PA	D000982	Antipruritics
MeSH PA	D003879	Dermatologic Agents
MeSH PA	D005765	Gastrointestinal Agents
MeSH PA	D006633	Histamine Antagonists
MeSH PA	D006634	Histamine H1 Antagonists
MeSH PA	D012702	Serotonin Antagonists
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D018490	Serotonin Agents
MeSH PA	D018926	Anti-Allergic Agents
CHEBI has role	CHEBI:22587	antiviral agent
CHEBI has role	CHEBI:35480	analgesic
CHEBI has role	CHEBI:37955	H<small><sub>1</sub></small>-receptor antagonist
CHEBI has role	CHEBI:48279	serotonergic antagonist
CHEBI has role	CHEBI:50857	anti-allergic agent
CHEBI has role	CHEBI:55324	gastrointestinal drug
CHEBI has role	CHEBI:59683	antipruritic drug

Related Drugs by ATC class:

R06AX Other antihistamines for systemic use 26 drugs

acrivastineantazolineastemizoleazatadineazelastinebamipinebilastinedeptropinedesloratadineebastineepinastinefexofenadine show all 26 →

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Dermatographic urticaria	indication	7632005	DOID:743
Allergic rhinitis	indication	61582004
Nasal discharge	indication	64531003
Nasal congestion	indication	68235000
Sneezing	indication	76067001
Urticaria	indication	126485001
Itching of skin	indication	418363000
Allergic conjunctivitis	indication	473460002	DOID:11204
Serotonin syndrome	off-label use	371089000
Muscle spasticity of spinal origin	off-label use	416830008
SSRI induced sexual dysfunction	off-label use	425528008
Ocular hypertension	contraindication	4210003	DOID:9282
Peptic ulcer	contraindication	13200003	DOID:750
Hyperthyroidism	contraindication	34486009	DOID:7998
Hypertensive disorder	contraindication	38341003	DOID:10763
Chronic idiopathic constipation	contraindication	82934008
Bladder outflow obstruction	contraindication	236645006
Benign prostatic hyperplasia	contraindication	266569009
Retention of urine	contraindication	267064002
Angle-closure glaucoma	contraindication	392291006	DOID:13550

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.8	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Histamine H1 receptor	GPCR	P35367	HRH1_HUMAN	ANTAGONIST	Ki	10.22		WOMBAT-PK	CHEMBL
5-hydroxytryptamine receptor 6	GPCR	P50406	5HT6R_HUMAN		Ki	6.80		WOMBAT-PK
5-hydroxytryptamine receptor 7	GPCR	P34969	5HT7R_HUMAN		Ki	6.90		WOMBAT-PK
Alpha-1A adrenergic receptor	GPCR	P35348	ADA1A_HUMAN		Ki	7.40		WOMBAT-PK
5-hydroxytryptamine receptor 2B	GPCR	P41595	5HT2B_HUMAN		Ki	8.81		WOMBAT-PK
D(1A) dopamine receptor	GPCR	P21728	DRD1_HUMAN		Ki	6.93		WOMBAT-PK
D(2) dopamine receptor	GPCR	P14416	DRD2_HUMAN		Ki	6.95		WOMBAT-PK
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN		Ki	6.98		DRUG MATRIX
Potassium voltage-gated channel subfamily H member 2	Ion channel	Q12809	KCNH2_HUMAN		Ki	4.86		DRUG MATRIX
Multidrug resistance protein 1	Transporter	P08183	MDR1_HUMAN					WOMBAT-PK
Sodium-dependent serotonin transporter	Transporter	P31645	SC6A4_HUMAN		Ki	5.39		CHEMBL
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN		Ki	6.54		CHEMBL
5-hydroxytryptamine receptor 1A	GPCR	P08908	5HT1A_HUMAN		Ki	7.23		WOMBAT-PK
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN		Ki	8.42		WOMBAT-PK
Alpha-2B adrenergic receptor	GPCR	P18089	ADA2B_HUMAN		Ki	7.77		DRUG MATRIX
D(3) dopamine receptor	GPCR	P35462	DRD3_HUMAN		Ki	8.10		WOMBAT-PK
Histamine H2 receptor	GPCR	P25021	HRH2_HUMAN		Ki	6.71		DRUG MATRIX
Histamine H4 receptor	GPCR	Q9H3N8	HRH4_HUMAN		Ki	8.19		WOMBAT-PK
Muscarinic acetylcholine receptor M1	GPCR	P11229	ACM1_HUMAN		Ki	8		WOMBAT-PK
Muscarinic acetylcholine receptor M2	GPCR	P08172	ACM2_HUMAN		Ki	8		WOMBAT-PK
Muscarinic acetylcholine receptor M3	GPCR	P20309	ACM3_HUMAN		Ki	8		WOMBAT-PK
Muscarinic acetylcholine receptor M4	GPCR	P08173	ACM4_HUMAN		Ki	8.66		DRUG MATRIX
Muscarinic acetylcholine receptor M5	GPCR	P08912	ACM5_HUMAN		Ki	8.56		DRUG MATRIX
5-hydroxytryptamine receptor 1D	GPCR	P28221	5HT1D_HUMAN		Ki	5.89		PDSP
Alpha-2C adrenergic receptor	GPCR	P18825	ADA2C_HUMAN		Ki	6.73		DRUG MATRIX
Alpha-1D adrenergic receptor	GPCR	P25100	ADA1D_HUMAN		Ki	6.90		WOMBAT-PK
Alpha-1B adrenergic receptor	GPCR	P35368	ADA1B_HUMAN		Ki	7.60		WOMBAT-PK
Calmodulin	Cytosolic other	P0DP23 P0DP24 P0DP25	CALM1_HUMAN CALM2_HUMAN CALM3_HUMAN					WOMBAT-PK
Sodium channel alpha subunits; brain (Types I, II, III)	Ion channel	P35498 Q99250 Q9NY46	SCN1A_HUMAN SCN2A_HUMAN SCN3A_HUMAN		IC50	6		CHEMBL
5-hydroxytryptamine receptor 2C	GPCR	P28335	5HT2C_HUMAN		Ki	8.65		WOMBAT-PK
Histone-lysine N-methyltransferase SETD7	Enzyme	Q8WTS6	SETD7_HUMAN		IC50	4.70		CHEMBL
Alpha-1B adrenergic receptor	GPCR		ADA1B_RAT		Ki	7.36		DRUG MATRIX
5-hydroxytryptamine receptor 1B	GPCR		5HT1B_RAT		Ki	5.90		DRUG MATRIX
Alpha-1A adrenergic receptor	GPCR		ADA1A_RAT		IC50	6.62		CHEMBL
Histamine H1 receptor	GPCR		HRH1_CAVPO		Kd	9		CHEMBL
D(2) dopamine receptor	GPCR		DRD2_RAT		IC50	6.85		CHEMBL
5-hydroxytryptamine receptor 1A	GPCR		5HT1A_RAT		IC50	6.91		CHEMBL
5-hydroxytryptamine receptor 2A	GPCR		5HT2A_RAT		Ki	8.80		CHEMBL
5-hydroxytryptamine receptor 7	GPCR		5HT7R_RAT		Ki	7.30		CHEMBL
Sodium-dependent noradrenaline transporter	Transporter		SC6A2_MOUSE		Ki	6.54		CHEMBL
5-hydroxytryptamine receptor 2C	GPCR		5HT2C_MOUSE		Ki	7.96		CHEMBL
D(2) dopamine receptor	GPCR		DRD2_MOUSE		Ki	6.95		CHEMBL
Sodium-dependent serotonin transporter	Transporter		SC6A4_MOUSE		Ki	5.39		CHEMBL
5-hydroxytryptamine receptor 6	GPCR		5HT6R_RAT	ANTAGONIST	Ki	6.90		IUPHAR
Muscarinic acetylcholine receptor	GPCR		ACM1_RAT ACM3_RAT ACM4_RAT ACM5_RAT ACM2_RAT		Ki	8.40		CHEMBL
Dopamine receptor	GPCR		DRD1_RAT DRD3_RAT DRD5_RAT DRD4_RAT DRD2_RAT		Ki	7.20		CHEMBL
Serotonin 2 (5-HT2) receptor	GPCR		5HT2C_RAT 5HT2A_RAT 5HT2B_RAT		IC50	8.51		CHEMBL

External reference:

ID	Source
4019701	VUID
N0000147793	NUI
D02234	KEGG_DRUG
41354-29-4	SECONDARY_CAS_RN
104592	RXNORM
C0010620	UMLSCUI
CHEBI:4046	CHEBI
C7H	PDB_CHEM_ID
CHEMBL516	ChEMBL_ID
CHEMBL1716	ChEMBL_ID
DB00434	DRUGBANK_ID
D003533	MESH_DESCRIPTOR_UI
2913	PUBCHEM_CID
277	IUPHAR_LIGAND_ID
872	INN_ID
2YHB6175DO	UNII
2249	MMSL
331	MMSL
4522	MMSL
d00790	MMSL
001537	NDDF
004617	NDDF
15352003	SNOMEDCT_US
26462003	SNOMEDCT_US
372683000	SNOMEDCT_US
4017931	VANDF
4019701	VANDF

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Cyproheptadine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0115-1757	TABLET	4 mg	ORAL	ANDA	21 sections
CYPROHEPTADINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	0463-6080	TABLET	4 mg	ORAL	ANDA	11 sections
Cyproheptadine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	10135-638	TABLET	4 mg	ORAL	ANDA	21 sections
Cyproheptadine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	16571-805	TABLET	4 mg	ORAL	ANDA	13 sections
Cyproheptadine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	17856-0504	SYRUP	2 mg	ORAL	ANDA	17 sections
Cyproheptadine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	27808-099	SYRUP	2 mg	ORAL	ANDA	19 sections
Cyproheptadine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	39328-544	SOLUTION	2 mg	ORAL	ANDA	21 sections
Cyproheptadine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	42708-177	TABLET	4 mg	ORAL	ANDA	20 sections
CYPROHEPTADINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	42708-187	TABLET	4 mg	ORAL	ANDA	18 sections
Cyproheptadine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	50090-4724	TABLET	4 mg	ORAL	ANDA	21 sections
Cyproheptadine Hydrochloride	Human Prescription Drug Label	1	50090-5491	TABLET	4 mg	ORAL	ANDA	20 sections
CYPROHEPTADINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	50090-6129	TABLET	4 mg	ORAL	ANDA	18 sections
Cyproheptadine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	50268-201	TABLET	4 mg	ORAL	ANDA	21 sections
CYPROHEPTADINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	50742-190	TABLET	4 mg	ORAL	ANDA	21 sections
CYPROHEPTADINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	51407-272	TABLET	4 mg	ORAL	ANDA	21 sections
Cyproheptadine Hydrochloride	Human Prescription Drug Label	1	52817-210	TABLET	4 mg	ORAL	ANDA	20 sections
Cyproheptadine Hydrochloride	Human Prescription Drug Label	1	52817-415	TABLET	4 mg	ORAL	ANDA	20 sections
Cyproheptadine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	53808-0829	TABLET	4 mg	ORAL	ANDA	21 sections
CYPROHEPTADINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	53808-0950	TABLET	4 mg	ORAL	ANDA	19 sections
Cyproheptadine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	53808-1030	TABLET	4 mg	ORAL	ANDA	21 sections
Cyproheptadine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	54868-1332	TABLET	4 mg	ORAL	ANDA	11 sections
Cyproheptadine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	54868-4338	SYRUP	2 mg	ORAL	ANDA	18 sections
cyproheptadine hydrochloride solution	HUMAN PRESCRIPTION DRUG LABEL	1	58657-697	SOLUTION	2 mg	ORAL	ANDA	11 sections
cyproheptadine hydrochloride solution	HUMAN PRESCRIPTION DRUG LABEL	1	58657-697	SOLUTION	2 mg	ORAL	ANDA	11 sections
Cyproheptadine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	62033-0346	TABLET	4 mg	ORAL	Export only	10 sections
Cyproheptadine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	62135-236	TABLET	4 mg	ORAL	ANDA	12 sections
CYPROHEPTADINE	HUMAN PRESCRIPTION DRUG LABEL	1	62135-949	SYRUP	2 mg	ORAL	ANDA	11 sections
CYPROHEPTADINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	64380-795	TABLET	4 mg	ORAL	ANDA	11 sections
Cyproheptadine Hydrochloride	Human Prescription Drug Label	1	64980-504	SYRUP	2 mg	ORAL	ANDA	17 sections
Cyproheptadine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	68151-1728	SYRUP	2 mg	ORAL	ANDA	17 sections